Copyright
©2012 Baishideng Publishing Group Co.
World J Cardiol. Feb 26, 2012; 4(2): 36-47
Published online Feb 26, 2012. doi: 10.4330/wjc.v4.i2.36
Published online Feb 26, 2012. doi: 10.4330/wjc.v4.i2.36
Table 2 Prevalence of cardiovascular risk factors and history of myocardial infarction and cardiac surgery stratified by gender
Author | Design | Study population | Patients | Age (mean, yr) | P | Hypertension (%) | P | Diabetes (%) | P | Smoking (%) | P | History of MI (%) | P | History of cardiac surgery (%) | P | ||||||||
study/date | Men | Women | Men | Women | Men | Women | Men | Women | Men | Women | Men | Women | Men | Women | |||||||||
Reynolds et al[30] 2007 | RCT | MI | 12 498 | 4090 | 59.5 | 67.0 | < 0.001 | 29.7 | 47.3 | < 0.001 | 14.4 | 21.0 | < 0.001 | 49.7 | 34.3 | < 0.001 | 16.4 | 12.5 | < 0.001 | CABG | 3.7 | 2.2 | < 0.001 |
PCI | 7.5 | 4.5 | < 0.001 | ||||||||||||||||||||
Moriel et al[28] 2005 | Pros cohort | ACS | 820 | 511 | 78 | 79 | 0.12 | 58 | 74 | < 0.001 | 33 | 40 | 0.007 | 13 | 5 | < 0.001 | 39 | 29 | < 0.001 | CABG | 14 | 7 | < 0.001 |
PCI | 21 | 11 | < 0.001 | ||||||||||||||||||||
Herlitz et al[18] 2009 | Retro cohort | AMI | 835 | 588 | 72.7 | 79.2 | < 0.0001 | 46 | 56 | 0.01 | 24 | 21 | NS | 22 | 16 | NS | 42 | 33 | < 0.0001 | CABG | 10 | 7 | 0.06 |
PCI | 7 | 5 | 0.32 | ||||||||||||||||||||
Mehilli et al[54] 2002 | Pros cohort | AMI | 1435 | 502 | 60.7 | 70.3 | < 0.001 | 61.0 | 72.9 | < 0.001 | 18.0 | 25.3 | < 0.001 | 43.1 | 25.9 | < 0.001 | 22.1 | 16.3 | 0.001 | CABG | 6.1 | 3.4 | 0.02 |
PCI | 10.7 | 7.6 | 0.04 | ||||||||||||||||||||
Mueller et al[55] 2002 | Pros cohort | MI | 1033 | 417 | 64 | 68 | 0.01 | 60 | 72 | 0.01 | 19 | 23 | 0.15 | 33 | 21 | 0.01 | 37 | 24 | 0.01 | CABG | 17 | 6 | 0.01 |
PCI | 24 | 21 | 0.20 | ||||||||||||||||||||
Toumpoulis et al[34] 2006 | Pros cohort | CABG | 2598 | 1162 | 63.2 | 66.2 | < 0.001 | 65.9 | 79.4 | < 0.001 | 28.8 | 45.5 | < 0.001 | 16.1 | 12.9 | 0.011 | 50.7 | 46.1 | 0.010 | CABG | 7.8 | 5.3 | 0.006 |
PCI | 10.9 | 12.8 | 0.093 | ||||||||||||||||||||
Dallongevillle et al[15] 2010 | Pros cohort | ACS | 6698 | 2268 | 62.2 | 65.8 | < 0.0001 | 80.3 | 87.9 | < 0.0001 | 33.6 | 38.4 | 0.009 | 19.3 | 11.0 | < 0.0001 | 19.1 | 20.6 | < 0.0001 | CABG | 20.4 | 17.2 | < 0.0001 |
Anand et al[9] 2005 | Trial | ACS | 7726 | 4836 | 62.7 | 66.5 | 0.0001 | 53 | 68.8 | 0.0001 | 20.9 | 24.6 | 0.0001 | 76.4 | 37.4 | 0.0001 | 36.9 | 23.9 | 0.0001 | CABG | 13.3 | 6.8 | 0.0001 |
PCI | 11.5 | 7.2 | 0.0001 | ||||||||||||||||||||
Matsui et al[26] 2002 | Retro cohort | AMI | 346 | 136 | 62.9 | 70.4 | 44 | 54 | 0.047 | 25 | 33 | 0.078 | 60 | 19 | 0.001 | 18 | 15 | 0.517 | CABG | 1 | 1 | 0.556 | |
PCI | 12 | 4 | 0.016 | ||||||||||||||||||||
Tizón-Marcos et al[33] 2009 | RCT | PCI | 1050 | 298 | 59.7 | 62.5 | 49 | 59 | 0.004 | 17 | 20 | 0.19 | 32 | 36 | 0.23 | 45 | 41 | 0.19 | CABG | 6.3 | 6.4 | 1.00 | |
PCI | 21 | 14 | 0.016 | ||||||||||||||||||||
Reina et al[51] 2007 | Pros cohort | AMI | 4641 | 1568 | 64 | 71 | < 0.01 | 41.0 | 61.1 | < 0.01 | 25.5 | 41.2 | < 0.01 | 53.6 | 15.7 | < 0.01 | 16.6 | 13.0 | < 0.01 | Total | 7.2 | 12.0 | < 0.01 |
Thompson et al[53] 2006 | Pros cohort | PCI | 807 | 359 | 61.7 | 67.7 | < 0.001 | 59.3 | 67.8 | 0.006 | 23.8 | 30.1 | 0.03 | 47.4 | 38.5 | 0.005 | 25.2 | 22.4 | 0.33 | CABG | 8.3 | 7.2 | 0.53 |
PCI | 28.3 | 24.6 | 0.20 | ||||||||||||||||||||
Lee et al[78] | Pros cohort | STEMI | 2954 | 1083 | 60.7 | 72.1 | < 0.001 | 40.2 | 59.7 | < 0.001 | 23.1 | 31.4 | < 0.001 | 58.8 | 14.7 | < 0.001 | 3.6 | 2.9 | 0.239 | CABG | 0.5 | 0.3 | 0.330 |
2008 | PCI | 4.3 | 2.8 | 0.023 | |||||||||||||||||||
Jankowski et al[46] 2007 | Pros cohort | CAD + PCI | 738 | 187 | 57.5 | 60.6 | < 0.001 | 72.6 | 87.8 | < 0.001 | 14.5 | 21.3 | < 0.05 | 13.6 | 6.4 | < 0.01 | 63.2 | 66.0 | NS | CABG | 1.5 | 0.5 | NS |
PCI | 8.8 | 8.5 | NS | ||||||||||||||||||||
Duvernoy et al[43] 2010 | Pros cohort | PCI | 14848 | 7877 | 61.9 | 66.9 | < 0.001 | 71.0 | 82.5 | < 0.001 | 29.2 | 38.5 | < 0.001 | 27.3 | 21.7 | < 0.001 | 36.0 | 32.6 | < 0.001 | CABG | 21.5 | 17.4 | < 0.001 |
PCI | 41.8 | 38.9 | < 0.001 | ||||||||||||||||||||
Lansky et al[22] 2005 | RCT | AMI + PTCA | 1520 | 562 | 57.0 | 66.0 | < 0.001 | 29.0 | 59.3 | < 0.001 | 14.0 | 25.7 | < 0.001 | 45.3 | 37.4 | 0.001 | 15.7 | 8.4 | < 0.001 | PCI | 12.7 | 7.1 | < 0.001 |
Lansky et al[67] 2009 | RCT | PCI | 687 | 314 | 61.8 | 65.9 | < 0.0001 | 72.7 | 81.5 | 0.0026 | 25.7 | 36.3 | 0.0007 | 24.0 | 21.2 | 0.3711 | 21.9 | 13.6 | 0.0022 | Total | 34.1 | 25.5 | 0.0066 |
De Luca et al[41] 2004 | Pros cohort | STEMI | 1195 | 353 | 59 | 66 | < 0.001 | 24 | 39 | < 0.001 | 8.7 | 15.8 | < 0.001 | 52.1 | 42.7 | 0.002 | 11.6 | 7.1 | 0.014 | CABG | 2.1 | 1.7 | NS |
PCI | 5.3 | 1.7 | 0.004 | ||||||||||||||||||||
De Luca et al[42] 2010 | Trail | STEMI | 1283 | 379 | 59 | 67 | < 0.001 | 39.1 | 52.5 | < 0.001 | 15.3 | 22.4 | < 0.001 | 56 | 36.9 | < 0.001 | 9.2 | 7.7 | 0.35 | Total | 7.7 | 7.6 | 0.93 |
Bufe et al[62] | Pros cohort | STEMI + PCI | 376 | 124 | 58 | 65 | < 0.001 | 66 | 54.8 | 0.055 | 11.2 | 24.2 | < 0.001 | 67.3 | 40.3 | < 0.001 | 11.7 | 8.9 | 0.479 | CABG | 5.6 | 0.8 | 0.046 |
2010 | PCI | 5.6 | 4.0 | 0.658 | |||||||||||||||||||
Carrabba et al[40] 2004 | Pros cohort | STEMI | 627 | 293 | 67.7 | 76.3 | 0.001 | 45.3 | 60.1 | < 0.001 | 22.7 | 25.3 | 0.385 | 34.1 | 14.3 | < 0.001 | 17.2 | 14.7 | 0.331 | CABG | 2.6 | 1.0 | 0.129 |
PCI | 5.9 | 2.1 | 0.010 | ||||||||||||||||||||
Lawesson et al[24] 2010 | Retro cohort | STEMI aged < 46 | 1748 | 384 | 40.8 | 40.4 | 0.14 | 13.9 | 21.7 | < 0.001 | 12.4 | 18.5 | 0.002 | 58.0 | 63.9 | 0.04 | 6.6 | 5.2 | 0.30 | CABG | 0.8 | 0.3 | 0.25 |
PCI | 2.5 | 1.9 | 0.46 | ||||||||||||||||||||
Berger et al[10] 2006 | Pros cohort | PCI | 2953 | 1331 | 61.9 | 66.8 | < 0.001 | 66 | 78 | < 0.001 | 22 | 36 | < 0.001 | 15 | 10 | < 0.001 | 36 | 33 | 0.08 | CABG | 19 | 14 | 0.001 |
PCI | 26 | 24 | 0.137 | ||||||||||||||||||||
Chiu et al[13] | Pros cohort | PCI | 12 738 | 5301 | 62.3 | 66.5 | < 0.001 | 58 | 71 | < 0.001 | 24 | 34 | < 0.001 | 21 | 20 | 0.01 | 43 | 42 | 0.29 | CABG | 30 | 21 | < 0.001 |
2004 | PCI | 6 | 4 | < 0.001 | |||||||||||||||||||
Koch et al[20] | Pros cohort | CABG | 1588 | 460 | 51.7 | 70.2 | 0.0001 | 22.5 | 36.3 | 0.0001 | 71.5 | 49.6 | 0.0001 | 14.3 | 10.7 | 0.044 | CABG | 14.4 | 7.0 | 0.0001 | |||
2003 | PCI | 15.4 | 16.3 | 0.6249 | |||||||||||||||||||
Setoguchi et al[31] 2008 | Pros cohort | AMI | 317 | 1308 | 80 | 82 | < 0.001 | 71 | 80 | 0.001 | 33 | 39 | 0.03 | 15 | 10 | 0.01 | 52 | 37 | < 0.001 | CABG | 18 | 13 | 0.03 |
PCI | 13 | 9 | 0.02 |
- Citation: Claassen M, Sybrandy KC, Appelman YE, Asselbergs FW. Gender gap in acute coronary heart disease: Myth or reality? World J Cardiol 2012; 4(2): 36-47
- URL: https://www.wjgnet.com/1949-8462/full/v4/i2/36.htm
- DOI: https://dx.doi.org/10.4330/wjc.v4.i2.36